Overview

Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Lorsatana + Hydrochlorothiazide Produced By Lab Hypermarcas S/A. In Healthy Subjects

Status:
Unknown status

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

The objective of this clinical study, randomized, crossover is to evaluate the pharmacokinetic profile of the polypill (atorvastatin + lorsatana + hydrochlorothiazide) Laboratory Hypermarcas S / A, in relation to drugs Citalor ® (atovastatina - Pfizer) and Hyzaar ® (losartan + hydrochlorothiazide - Merck Sharp & Dohme) by comparing the serum concentration of analytes unchanged (AT, LS and HCTZ) in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Azidus Brasil

Treatments:

Atorvastatin
Atorvastatin Calcium
Hydrochlorothiazide
Losartan